Renal Cancer - Results from #1820

The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. October 14, 2021

Robotic-Assisted Partial Nephrectomy: Techniques to Improve Clinical Outcomes. October 14, 2021

Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States. October 13, 2021

Comparison of Perioperative, Renal Functional, and Oncological Outcomes Between Off-Clamp and On-Clamp Robot-Assisted Partial Nephrectomy for Renal Tumors: An Updated Evidence-Based Analysis. October 13, 2021

Association Between Sarcopenia and Survival of Patients with Organ-Confined Renal Cell Carcinoma after Radical Nephrectomy. October 12, 2021

Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. October 12, 2021

Comparison of Perioperative Outcomes Between Laparoscopic and Open Partial Nephrectomy for Different Complexity Renal Cell Carcinoma Based on the R.E.N.A.L. Nephrometry Score. October 11, 2021

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). October 11, 2021

Characterizing the tumor microenvironment in rare renal cancer histological types. October 8, 2021

Identification of Prognostic Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma. October 8, 2021

Metastasectomy in kidney cancer: current indications and treatment approaches. October 7, 2021

Parenchymal Volume Replacement by Renal Cell Carcinoma Prior to Intervention: Predictive Factors and Functional Implications. October 7, 2021

Renal cell carcinoma with unusual metachronous metastasis up to 22 years after nephrectomy: two case reports. October 7, 2021

Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. October 6, 2021

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. October 6, 2021

Nobel Winner Dr. James P. “Jim” Allison to Give Keynote Address at IKCS 2021 October 5, 2021

Inflammatory response markers and survival prediction in patients with renal cell carcinoma. October 5, 2021

CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma. October 5, 2021

Limited Association Between Ascorbate Concentrations and Vitamin C Transporters in Renal Cell Carcinoma Cells and Clinical Samples. October 4, 2021

Morphomics Can Predict Oncological Features and Survival of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy. October 4, 2021

Page 92 of 456